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Objective: To assess the usefulness of PPD antibody measurement in the diagnosis
of tuberculosis in patients admitted to hospital.
Patients and methods: Sixty-one patients presenting with active tuberculosis, and
215 control patients were included in the study. Initial serum PPD antibody titres
were determined with a macrophage uptake Fluorescent antibody test (MuFat) to
construct a discrimination model between Tuberculosis (TB) and non-TB. We also
retrospectively collected clinical parameters of the TB patients at presentation.
Univariate and multivariate logistic regression are used to identify variables
predicting high antibody titres.
Results: In TB patients, the presence of clinical symptoms (OR ¼ 10:63) and the
presence of at least two concurrent non-lymph node disease localizations outside
thorax and abdomen (OR ¼ 13:94) are necessary and sufficient to predict high
titres.
The logistic model shows a significant contribution of the 2log (titre) to the
discrimination between TB and non-TB patients. At a cut-off value of 128, a
specificity, sensitivity, and positive predictive and negative predictive values of 97%,
39%, 80% and 85%, respectively, are calculated in the study cohort.Elsevier Ltd. All rights reserved.
tation rate of erythrocytes; CI, confidence interval; Hb, haemoglobin concentration; MuFat,
ibody test; LN, lymph nodes; NPV, negative predictive value; OR, odds ratio; PPV, positive
ting characteristic; TB, tuberculosis; ZN, Ziehl-Neelsen
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timely diagnosis of difficult-to-diagnose TB patients. The results of this retrospective
study will have to be confirmed in further prospective studies.
& 2004 Elsevier Ltd. All rights reserved.Introduction
Timely diagnosis is crucial in confining tuberculosis
(TB) morbidity and disease transmission. In several
low-incidence countries, diagnostic delay constitu-
tes a risk to TB morbidity and mortality.1,2
Diagnosis, especially of sputum smear-negative
TB, can be cumbersome because of the variety of
symptoms and localizations, and the time lapse
between initial suspicion and confirmation by
culture.3 Serodiagnosis has been widely explored
in search for a rapid alternative to the standard of
mycobacterium identification and as a way to
circumvent the need to collect proper bacteriolo-
gical specimens.4 Numerous serological tests using
various antigens and a variety of detection system
have been developed.5 Still, even the modern
ELISA-based tests give insufficient results for
clinical application as a useful screening tool.
Although until now disappointing as a screening
instrument, surprisingly little satisfactory effort is
given to serology as a diagnostic tool in clinically ill
TB patients.6 With this background, the aims of the
present study were:1. to identify variables predicting high TB antibody
titres from historical data;2. to construct a discrimination model and cut-off
values between TB and non-TB patients in a case
control design.
By using a PPD antibody assay in a fixed clinical
setting, applied at the moment of presentation of
the patient, we determined the appropriate sensi-
tivity and specificity levels of the test in the study
cohort. Based on the results, we discuss the
potential use of this test in clinically ill patients
sent to hospital for diagnosis and treatment.Patients and methods
Patients
For this study patients were recruited from the
Zeeland provincial reference laboratory database
during the period 1992–1998. The reference
laboratory covers the four hospitals and the TB
clinic in the province. The database containspersonal data (age, sex, ordering department),
laboratory data (TB antibody titre), sample
type, results of culture and smear, clinical
chemistry) and one or two clinical symptoms as
stated on the order form by the ordering physician.
TB antibody tests were requested by clinicians in
the provincial hospitals and by Public Health
Officers from the Department of Tuberculosis
Control, when TB was suspected or considered.
The retrospective study was done in the cohort of
patients investigated for TB in the sequence they
showed up.
The availability of the first test result pro patient
(i.e. within two days of presentation) and the
availability of the results of simultaneous bacter-
iological cultures (Lo¨wenstein or Coletsos cultures)
were a prerequisite for inclusion. Patients with
hampered immune response (HIV positive, concur-
rent tumour or immune disease, treatment with
corticosteroids or cytostatics7,8), under six years of
age,9 or with a medical history of TB within the last
15 years were excluded.
Patients in the database with TB were regarded
as study subjects. Diagnosis of TB was applicable if
the patients were registered by the Dutch Public
Health TB Index, i.e. met registration protocol
criteria.
From the 68 TB patients found, we excluded 7 TB
patients because of HIV positivity (n ¼ 1), concur-
rent tumour or immune disease (n ¼ 2), treatment
with corticosteroids or cytostatics (n ¼ 1) or
medical history of TB in the last 15 years (n ¼ 3).
Of the 61 TB patients included in the study, TB was
confirmed by culture of Mycobacterium Tuberculo-
sis (58 study subjects), or the patients met the
criteria otherwise (two study subjects as traced
contacts with a radiological diagnosis of primo TB,
and one study subject with a radiological diagnosis
and a confirmation of M. Tuberculosis presence by
polymerase chain reaction).
All TB patients gave informed consent. Clinical
data of the TB patients were obtained from hospital
records and the Public Health Office.
In the same period 1992–1998 the Dutch Public
Health Authority registered 217 new TB patients in
the province of Zeeland, less than 2% of them
younger than six years. All registered TB patients
were treated with antituberculous drugs.10 Se-
venty-five percent of them (75%) were registered
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as only culture positive.10,11
As we excluded seven TB patients because of HIV
positivity (n ¼ 1), concurrent tumour or immune
disease (n ¼ 2), treatment with corticosteroids or
cytostatics (n ¼ 1) or medical history of TB in the
last 15 years (n ¼ 3), there are 149 officially
registered TB patients not included in the study.
Either they did not meet our prerequisite criteria
(test results available within 2 days of presenta-
tion), or they were not in the database at all (e.g.
traced contacts with primo infection).
Non-TB patients were selected by taking every
fourth TB antibody test result from the database
and constituted the control group for comparison.
Diagnosis of TB in these patients was excluded by
concomitant negative TB culture results and by
cross-checking with the Dutch Public Health TB
Index. Control patients were also not registered in
the Index in the two years following the entry date
in our database. Other diagnoses were confirmed by
bacteriological culture, virological testing or histo-
logical examination. The resulting group of 215
(control group) presented with respiratory (pneu-
monia, recurrent bronchitis, interstitial lung dis-
ease, mediastinal mass) or non-respiratory clinical
signs and symptoms (lymphadenopathy, arthritis,
febris e.c.i., malaise, anaemia, osteitis, non-
specific abdominal pains).
Microbiological samples were obtained by spon-
taneous expectoration, sputum induction, bron-
chial washing, broncho-alveolar lavage, aspiration
or open-tissue biopsy. Samples were processed for
acid-fast bacilli smear examination (Ziehl-Neelsen
staining (ZN)) or for culture as usual.10 Blood
samples drawn within 48 h after the patients’ first
presentation were used to determine haemoglobin
level (Hb), blood sedimentation of erythrocytes
(BSE), and TB antibody titre.Macrophage uptake of fluorescent antibody
test (MuFat)
At arrival in the laboratory, sera were tested for
antibodies against TB the MuFat, an non-commer-
cially available fluorescence test with purified
protein derivate (PPD; RIVM, Bilthoven; The Neth-
erlands) as antigen as described before.12 PPD-
presenting macrophages were obtained by irrigat-
ing (phosphate-buffered saline PBS, pH=7.2) the
peritoneal cavity of euthanized C57 black mice
inoculated intraperoneally 24 h earlier with 2mg of
PPD. The resulting macrophage suspension was
washed and diluted to a turbidity of McFarland 3.
Four drops of the suspension were transferred bymeans of a platinum loop to each microscope slide
and these were allowed to dry in the air. After
fixation (acetone, 10min, 4 1C), the slides can be
stored at 20 1C. Before use the slides need to be
washed in cold PBS for 10min. The MuFat was
carried out on serial dilutions of patient sera
according to standard procedure. One series of
serum dilutions, from dilution 1:16 onwards, was
tested per slide. The serum dilutions were trans-
ferred to the dried spots of antigen, and the slides
were incubated in a humid environment (30min,
room temperature). After a washing step (cold PBS,
10min), a titrated conjugate solution was added as
a second layer, and the slides were again incubated
in a humid environment (30min, room tempera-
ture).
The conjugate solution (rabbit antihuman Ig/
FITC (Fluorescein Isothiocyanate, Nordic Pharma-
ceuticals, Tilburg, The Netherlands) was pre-
absorbed with M. Avium suspension and was
titrated against a standard set of positive and
negative controls.
After a second washing step (cold PBS, 10min),
the slides were covered with cover slips and read
with a fluorescence microscope.
The highest dilution with a typical fluorescence
of the macrophages was interpreted as the titre
(1:16–1:512 or more). Results were recorded as the
(inverse) titre, e.g. 16 for a 1:16 diluted serum and
512 for a 1:512 or higher serum dilution. The
resulting titre was used as outcome variable in a
prediction model.Risk factors
Chest radiographs of TB patients were reviewed.
The extension of pulmonary features on each
patient’s X-ray was described as the number of
diseased lung quadrants or involvement of other
intrathoracic tissues (mediastinal lymph nodes
(LN), pleura fluid).
Further categories of clinical localization were
intra-abdominal (organs, mesenterium, LN, psoas
abscess); palpable peripheral lymph node localiza-
tions; other structures (superficial, e.g. skin,
fistula, pharynx wall or deep, such as bone, muscle,
intra-articular (other localization)). An individual
patient could at the same time fall into several
categories. The information on localizations was
obtained by the combination of accurate physical
and technical examination. Data for TB patients on
clinical signs and symptoms such as cough, fever,
sweating, fatigue or malaise, weight loss and other
signs and symptoms were collected as described
before10 and used as categorical parameters.
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Table 1 Characteristics of TB and control pa-
tients in the province of Zeeland.
TB patients
(n ¼ 61)
Controls
(n ¼ 215)
P
Age*
Mean (SD) 36.3 (19.6) 37.8 (18.6) 0.57*
Nationality
Dutch 24 (39%) 115 (53%) 0.06**
Gender
Male 39 (64%) 129 (60%) 0.66**
Origin
Hospital dept
Chest 22 (36%) 92 (43%)
Internal 10 (16%) 67 (31%)
Other 9 (13%) 27 (12%) 0.27***
TB clinic 20 (33%) 29 (14%)
All hospital depts 41 (67%) 186 (87%) o0.01**
TB titre
16 25 (41%) 188 (88%)
32 7 (11%) 14 (7%)
64 5 (8%) 7 (3%)
128 9 (15%) 3 (1%)
256 9 (15%) 2 (1%)
512 6 (10%) 1 (0%)
*Age in years; SD=Standard deviation; dept.=depart-
ment; n=number; %=percentage; P=P-values for statisti-
cally significant differences between TB and control
patients (*Mann-Whitney, **Fischer exact, ***X2 test).
R.F.C. Doveren et al.480Disease localizations, laboratory data, clinical
signs and symptoms, the actual disease history (i.e.
duration of the main clinical symptom in months)
and epidemiological data were all used as para-
meters for statistical analysis.
Statistical analysis
Comparisons between TB patients and controls
were made with the Mann–Whitney test in case of
quantitative variables, and the X2 test was used in
case of qualitative variables (i.e. Fisher’s exact test
for two-by-two tables). Values of Po0:05 were
considered as statistically significant. The number
of controls was based on power analysis. It was
calculated that for a case control design with 60
cases, more than 200 controls were needed
(power=90%, I ¼ 5%; P0 ¼ 15%; P1 ¼ 2%; M ¼ 3).
Univariate logistic regression was used to evalu-
ate the ability of the 2log (titre) to discriminate
between TB patients and controls. Because in
particular the 2log (titre) is expected to be non-
linearly related in the logistic regression model,
reasonable cut-off values to discriminate between
TB and non-TB are constructed.
At this point, the condition of weighted ‘costs’ of
misclassification of cases and non-cases was used.
In other words, the optimal cut-off value for a
particular titre was chosen so that the weighted
sum of sensitivity and the specificity to discrimi-
nate between TB patients and controls was max-
imal (that is, loss in specificity costs 5 times as
much as gain in sensitivity).
Multivariate logistic regression with forward
selection procedures was used to identify variables
that contributed independently to discriminate
high titre (dilution of 128 times or more) from
low titre (dilution of less than 128 times). Because
forward selection procedures did not identify other
important variables, P-values for entry in the
model were considered in order to find close
alternatives to the variables selected.13
Sensitivity, specificity, positive (PPV) and nega-
tive predictive values (NPV) were calculated and
crude or adjusted odds ratios (OR) with 95%
confidence intervals (95% CI) were presented.Results
Patient characteristics
The 61 TB patients and 215 control patients varied
in age from 6 to 88 years, the mean age of the TB
and control patients being 36.3 years and 37.8years, respectively (Table 1). TB and control
patients were admitted to the hospitals or the
provincial TB Public Health clinic. Table 2 shows the
characteristics of all TB patients. The relative
number of TB patients from the TB clinic, acquired
by passive case finding, was significantly higher
than the number of TB patients admitted to the
hospitals (Po0:01). There was no statistically
significant difference between the numbers of TB
and control patients who were admitted to the
chest, internal or other hospital departments.
Of the TB patients, 39 (64%) were male and 24
(39%) had the Dutch nationality. Twenty-five TB
patients (41%) were from Africa, three from Asian
countries and four from different European coun-
tries. The foreign TB patients were in The Nether-
lands as asylum seekers, immigrants or contract
workers. The control group had comparable per-
centages of patients from countries with high or
low TB incidence. There were no statistically
significant differences in age, gender or nationality
between the TB and control patients (Table 1).
Of the TB patients, 48 (79%) presented with at
least one intrathoracic TB localization, of which
three had a purely mediastinal LN TB, six had
pleural TB, and six had a miliary TB. Ten TB patients
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Table 2 Clinical characteristics of TB patients
(n ¼ 61).
TB Localization
Intra-thoracic 48 (79%)
Intra-abdominal 10 (16%)
Peripheral lymph nodes 7 (12%)
Other* 13 (22%)
Laboratory
Smear-negative 46 (75%)
Hb
Median (range) 8.3 (5.3–10.3)
BSE
Median (range) 34 (2–112)
Clinical symptoms
Cough 19 (31%)
Fever 11 (18%)
Weight loss 18 (30%)
Night sweat 8 (13%)
Fatigue 14 (23%)
Other symptomy 20 (33%)
Historyz 19 (31%)
*Other=e.g. skin, fistula, pharynx wall, bone, muscle,
intraarticular (multiple localization categories possible);
Hb=haemoglobin concentration (mmol/l); BSE=blood se-
dimentation rate of erythrocytes (mm/h).
yOther symptoms=e.g. localized pain, diarrhoea, hae-
moptysis, dyspnoea.
zHistory=history of the main symptom more than one
month preceding presentation.
Prognostic variables for high TB titres 481had at least one intra-abdominal localization,
seven had at least one peripheral LN localization
and 13 patients (22%) had at least another
localization of the process (Table 2).
At the time of presentation, 46 of the TB patients
(75%) had negative sputum ZN smears and two
patients had no smear performed. The TB patients
had a mean BSE of 43 (range 2–112) mm/h and a
mean Hb of 8.0 (range 5.3–10.3) mmol/l.
Cough was a symptom in 19 TB patients (31%), 18
patients had weight loss, and 37 patients (61%) had
at least one of the five categories of clinical
symptoms. Twenty patient (33%) had other symp-
toms (localized pains, diarrhoea, etc.) and 19
patients had a history of the symptoms lasting
more than one month.
All TB patients showed a favourable response to
antituberculous treatment except one patient who
died within one month after start of treatment.
Diagnosis of the six non-TB patients with titres of
at least 128 were: unknown (lost to follow-up-solitary pulmonary
nodule, pleural cap), sarcoidosis,
 death by cardiac insufficiency-cardiomegaly.
(Post-mortem examination showed no infection
focus), rheumatoid arthritis,
 pan-sinusitis and non-allergic bronchial asthma,
 non-specified, atypical pneumonia and diabetes
mellitus.Titres to predict TB
The distribution of TB titres of TB and non-TB
patients is shown in Table 1. The results of the
logistic model shows that 2log (titre) statistically
significantly contributes to discriminate between
TB and controls (Fig. 1). The crude OR for the
variable is 2.456 (95% CI: 1.889–3.194).
Fig. 1 shows the ROC curve of the titre to
discriminate between TB and control patients. The
area under the curve is 78%. Furthermore, the
optimal cut-off value using the weighted cost
principle was found at titre=128. At this threshold
of 128, a specificity, sensitivity, PPV and NPV of 97%
and 39%, 80% and 85%, respectively, was attained. A
prior disease probability of 0.1–0.2 for the clinical
subpopulation was estimated.
At the threshold of 128 for the ZN sputum
negative patients a PPV of 74% was calculated.
At a cut-off value of 512, TB can be predicted
with a specificity of 99.5%, a PPV of 86% and a
sensitivity of 9.8%.
Prognostic variables to predict high titres in
TB patients
Table 3 shows the crude OR to discriminate
between high (X128) titre and low (o128) TB
antibody titre in TB patients. Note that in this
section, in contrast to the previous one, titres are
studied in TB patients only.
The results of the univariate logistic regression
showed that several parameters were identified as
potential covariates. Only the localization para-
meters ‘lung quadrants’ (number of lung quadrants
involved), ‘extended’ (patients with 1 intra-ab-
dominal localization or at least 2 peripheral LN
localizations or other localizations, or involvement
of at least 3 lung quadrants) and ‘neither pulmon-
ary nor intra-abdominal’ (patients with two con-
current other localizations) could predict high
titres in TB patients, based on the level of
significance.
Of the laboratory parameters, BSE was a poten-
tial covariate of low-to-intermediate significance
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Figure 1 ROC curve of the 2log-TB antibody titres to
discriminate between TB and non-TB patients.
Table 3 Crude-odds ratios (95% confidence inter-
vals) of clinical and demographical patient char-
acteristics to predict high titre (X128) TB using
univariate logistic regression.
Variable* OR
Age 1.01 (0.98; 1.04)
Dutch 0.88 (0.33; 2.53)
Male 1.22 (0.55; 4.83)
Lung quadrants 1.79 (1.04; 3.11)
Pulmonary 7.20 (0.75; 68.89)
Extended 7.23 (2.19; 23.84)
Neither pulmonary nor
intra-abdominal
5.83 (1.07; 31.88)
BSE 1.02 (1.00; 1.04)
Hb 0.89 (0.56; 1.40)
Clinical symptoms 1.81 (1.07; 3.06)
Clinical presence 7.09 (2.22; 22.67)
*Lung quadrants=number of lung quadrants involved;
Pulmonary=presence of pulmonary localization(s); Exten-
ded=one abdominal localization, or at least two periph-
eral lymph node or other localizations, or at least three
lung quadrant localizations; Neither pulmonary nor intra-
abdominal=two concurrent other localizations; BSE=blood
sedimentation rate of erythrocytes; Hb=haemoglobin
concentration; Clinical symptoms=number of clinical
symptoms; Clinical presence=presence of clinical symp-
tom(s).
R.F.C. Doveren et al.482level. The parameters ‘clinical symptoms’ (total
number of clinical symptoms) and ‘clinical pre-
sence’ (presence of clinical symptoms) were found
to be potential covariates (intermediate- and high-
significance level, respectively). The actual disease
history did not give a potentially significantcontribution to a disease model. Demographical
parameters such as nationality (Dutch or not
Dutch), gender or age were also not significantly
related to high titre.
Table 4 shows the adjusted OR to predict high
titre and low titre using multivariate logistic
regression. All variables with statistically signifi-
cant crude OR were entered at the start of the
selection procedure. This selection procedure
shows that ‘neither pulmonary nor intra-abdom-
inal’ and ‘clinical presence’ are the only indepen-
dent variables sufficient and necessary to predict a
high titre, explaining 37% of the total variance
(R2 ¼ 37%).
Clinical variables as the total number of the
clinical symptoms or demographic variables did not
give an additional contribution to the prediction of
high titres (i.e. X128).Discussion
The present report studies the characteristics of a
TB antibody test in patients, when the diagnosis TB
was suspected or considered. It differs from other
studies in that it compares only TB and non-TB
patients from one adherence area14 who were
admitted to either a general hospital or specialist
clinic. A major finding in this study is the
identification of two independent factors, suffi-
cient for the prediction of high TB antibody titres.
To our knowledge, no other diagnostic serological
studies aimed at a subpopulation of sick patients
that present adjusted OR with confidence intervals,
have been published until today. In contrast to our
results, most models that find a clinical and
pulmonary factor as necessary and sufficient
determinants predicting TB only deal with patients
with pulmonary disease, and are aimed at infection
prevention.15,16 The presence of two concurrent
non-lymph node localizations outside thorax and
abdomen as predicting factor sustains the assump-
tion that not the (radiological) extensiveness of the
disease process but the total bacillary load at sites
far from the entry site explains the activation
status of the humeral response at the moment of
presentation. All patients with a low bacillary load
(pleuritis tuberculosa, primo TB, mediastinal TB),
in spite of the impressive radiological deviations
and sometimes considerable compression dyspnoea
in the last group, had very low to low titres.17,18
The only other predictor for high TB antibody
titres found in this study was the presence of
clinical symptoms. In The Netherlands most TB
patients found by contract tracing and without
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Table 4 Adjusted-odds ratios (95% confidence intervals) of patient characteristics to predict high titre (X128)
TB using multivariate logistic regression with forward selection procedures.
Variable* OR R2 AUC
Neither pulmonary nor intra-abdominal 13.94 (1.85; 105.01)
Clinical presence 10.63 (2.59; 43.67) 37% 78%
*Neither pulmonary nor intra-abdominal=two concurrent other localizations; Clinical presence=presence of clinical
symptom(s): R2=maximum rescaled R-squares indicating the % explained variance; AUC=area under the ROC curve (all variables
with statistically significant crude odds ratios were entered into the model).
Prognostic variables for high TB titres 483major clinical symptoms are not admitted to
hospital but are generally treated at home by the
Public Health Service and the study is not aimed at
this group of patients.19
Obviously, the study was restricted in that only
the clinical data set of TB patients was available.
Also no patients with cerebral or urinary TB were
present in the study. Further analysis with clinical
data of TB and non-TB patients could reveal other
contributing factors as the history of clinical
symptoms, and can give a more precise estimation
of the weight of contributing risk factors.
Unlike the results of others,18,20 our study
reflects a test of an acceptable discriminating
power (area under the ROC curve is 78%) and a
specificity, sensitivity and PPV of 97%, 39% and 80%.
Recalculation with only the use of the culture
confirmed TB patients gave similar results, not
surprisingly because of the limited number (3) of
otherwise defined TB patients.
In line with others who report lower rates of
seropositivity for extrapulmonary TB compared to
that for sputum smear-positive TB,21,22 there is no
reason to believe that the use of only sputum
smear-negative TB patients should alter the princi-
pal conclusions of the study.
Obviously, the results of the study cannot be
generalized to an open population. First, we chose
to limit this study of a serological test to
immunologically non-impaired patients. Second,
the study aims at the description of risk factors
for high antibody titre TB patients admitted to
hospital. The unexpectedly high TB prevalence in
the study cohort should not be confused with the
TB prevalence in contact groups (up to 5%) or
otherwise defined groups. Because PPV is a function
of the prevalence of TB, the described PPV applies
only to a hospital population of sick and difficult-to-
diagnose patients, i.e. without an obviously pul-
monary TB and with symptoms of extrapulmonary
or general disease. Clearly, the found cut-off value
has to be validated in future prospective studies.
As in many older tests, the MuFat test was
developed in veterinary studies and uses PPDtuberculin as an antigen.23 The macrophage system
and PPD can mimic the in vivo antigenic capacity
that evokes a broad humoral response.24 The
visually assessed test is liable to improvement as
standardization of flow cytometry is in progress.25
Recent reports use highly purified or recombinant
antigens that reach sensitivities of 60–80% and
specificities up to 97%,26–28 and it would be
interesting to study a set of these tests in a similar
clinical setting.
We think that the results of our study can be
useful in clinical practice. Clearly, this serological
test does not discriminate between mediastinal TB
and intrathoracic sarcoidosis. In our region, we
further estimate that less than 5% of the cumula-
tive number of incident TB patients could theore-
tically be identified with a high specificity.
Nevertheless, in at least seven smear-negative
patients out of the tested 61 TB patients (two
patients categorized as miliary TB, a pregnant TB
patient,10 three patients with abdominal TB) with
titres of at least 256, the test results made TB
probable and influenced the decision towards a
more active attitude, e.g. surgical exploration or
the start of a trial therapy, at least one month
before culture results were known.
We think that, if a proper selection of ZN smear-
negative, clinically ill patients is made and false
negative results are accepted, limited serological
TB testing can be useful in clinical decision-making
in low-incidence countries. This requires future
prospective studies with serological TB tests,
utilising complete and comprehensive databases.References
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